Decoy Therapeutics, Inc. (DCOY) Preclinical PK Supports Once-Weekly Intranasal Dosing

Decoy Therapeutics reported preclinical PK data showing a single intranasal dose of DCOY-CoV maintained drug levels above designed therapeutic concentrations in nasal mucosa and lung tissue for up to 7 days. The program is expected to enter clinical trials in 2027.Material DetailsContext by AI Anal…